Evidence map›Paper›PMID 31309348›Full record

Trial reportAIDS and behavior2019

A Pilot Study of a Mobile App to Support HIV Antiretroviral Therapy Adherence Among Men Who Have Sex with Men Who Use Stimulants.

Keith J Horvath, Sara Lammert, Richard F MacLehose, Thu Danh, Jason V Baker, Adam W Carrico

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS and behavior, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Keith J HorvathDivision of Epidemiology and Community Health, University of Minnesota, 1300 S. 2nd Street, Suite 300, Minneapolis, MN, USA. horva018@umn.edu.ORCID http://orcid.org/0000-0001-7569-2839
Sara LammertDivision of Epidemiology and Community Health, University of Minnesota, 1300 S. 2nd Street, Suite 300, Minneapolis, MN, USA.
Richard F MacLehoseDivision of Epidemiology and Community Health, University of Minnesota, 1300 S. 2nd Street, Suite 300, Minneapolis, MN, USA.
Thu DanhDivision of Epidemiology and Community Health, University of Minnesota, 1300 S. 2nd Street, Suite 300, Minneapolis, MN, USA.
Jason V BakerDivision of Infectious Diseases, Hennepin Healthcare, Minneapolis, MN, USA.
Adam W CarricoSchool of Medicine, University of Miami, Coral Gables, USA.
University of Minnesota · USUniversity of Miami · US

Funding

A Smart Phone App to Improve ART Adherence among HIV+ Stimulant-using MSMR34DA033833 · NIDA · UNIVERSITY OF MINNESOTA · PI HORVATH, KEITH JOSEPH · 2013 to 2015
$685k
National Institute on Drug Abuse R34DA033833NIDA NIH HHS R34 DA033833
6 · The paper itself

Abstract

APP+ is a theoretically-grounded mobile app intervention to improve antiretroviral (ART) adherence among men who have sex with men (MSM) who use stimulants. We assessed the feasibility and acceptability of APP+ in a six-month randomized controlled trial among a national sample of 90 MSM recruited online; secondarily, we examined changes in self-reported ART adherence by study arm. Retention at the final assessment was 82%, and acceptability ratings were comparable to other technology-based interventions. MSM in the APP+ group reported higher self-reported percentage ART adherence in the past 30 days at the four-month timepoint compared to a no-treatment control group (89.0% vs. 77.2%). However, once access to the app was removed after month four, group differences in ART adherence diminished by month six. APP+ may be a potentially promising intervention approach for MSM living with HIV who use stimulants but would require enhancements to optimize acceptability and demonstrate more sustained effects.

Indexed as

Drug MonitoringMobile ApplicationsText MessagingAdultAnti-Retroviral AgentsCentral Nervous System StimulantsHIV InfectionsHomosexuality, MaleHumansMalePilot ProjectsSubstance-Related DisordersAnti-Retroviral AgentsCentral Nervous System StimulantsDrug useHIV/AIDSMedication adherenceMobile app

Identifiers

PMID31309348
PMCPMC6803067
OpenAlexW2962075443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.